Chiome Bioscience Inc. (TSE:4583) entered into a contract to acquire 52.9% stake in LivTech Inc. from KSP No. 2 Limited Partnership Fund and KSP No. 3 Limited Partnership Fund managed by KSP Inc., Medical & Biological Laboratories Co., Ltd. (JASDAQ:4557), JAFCO Incubation No. 2 Venture Capital Investment Limited Partnership, Yume Fund No. 3, a fund of Yokohama Capital Co. Ltd., Life Science Venture Fund II managed by ReqMed Venture Capital and MBL Venture Capital Co., Ltd., Koji Nakamura and Reiko Nakayama for ¥87.8 million on December 16, 2013. Chiome Bioscience will acquire 225 B preferred shares of LivTech at a price of ¥390,000 million per share.

LivTech Inc. reported net assets of ¥0.12 million, total assets of ¥0.23 million, sales of ¥0.13 million, operating loss of ¥0.07 million and net loss of ¥0.07 million for period ended December 2012. The transaction is expected to be completed on December 25, 2013.